CKS1B as immunotherapy response prediction biomarker and application thereof

By detecting the expression level of CKS1B in esophageal squamous cell carcinoma tumor tissue, and using CKS1B inhibitors in combination with other active ingredients to prepare drugs, the problems of inaccurate prediction of immunotherapy response and immune escape in esophageal squamous cell carcinoma were solved. This resulted in tumor volume reduction and T cell function recovery, thus enhancing the efficacy of immunotherapy.

CN121622897APending Publication Date: 2026-03-10CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
0 Cites 1 Cited by

Patent Information

Application Number
CN202511837176.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-12-08
Publication Date
2026-03-10

AI Technical Summary

Technical Problem

In existing technologies, the prediction of response to immunotherapy for esophageal squamous cell carcinoma is inaccurate, and there are problems with immune escape and immune resistance. There is a lack of sensitive and specific biomarkers, and the combination strategies for immunotherapy lack personalized guidance.

Method used

Using CKS1B as a biomarker, the expression level of CKS1B in esophageal squamous cell carcinoma tumor tissue was detected to assess the sensitivity of patients to immunotherapy. A drug was prepared by combining CKS1B inhibitors with other active ingredients to promote CD8+ T cells to clear tumor cells, improve interferon signaling pathway and antigen presentation, and restore immune response.

Benefits of technology

It significantly reduces tumor volume, restores T cell function, overcomes immune escape mechanisms, improves the efficacy of immunotherapy, and enhances the treatment effect on esophageal squamous cell carcinoma.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicine, and provides CKS1B serving as an immunotherapy response prediction biomarker and application of the CKS1B, and according to the application, CKS1B serves as an immunotherapy response marker, and a CKS1B inhibitor is combined with an active component to treat a model mouse. In-vitro cell experiments are adopted to evaluate the immunotherapy prediction effect of the CKS1B as a biomarker on esophageal squamous carcinoma, a Cks1b overexpression tumor mouse model, a homologous mouse model and a human immune reconstruction mouse model are established, and a CKS1B inhibitor is combined with active ingredients to treat the two models; results show that the CKS1B inhibitor combined with the active component can promote removal of esophageal squamous carcinoma cells by CD8 + T cells, inhibit interferon signal channels and antigen presentation, effectively recover immune response, inhibit tumor cell proliferation and significantly reduce tumor volume, so as to achieve the purpose of treating esophageal squamous carcinoma.
Need to check novelty before this filing date? Find Prior Art